Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPONSE phase 3 trial of seladelpar versus placebo in primary biliary cholangitis
MOH_2021-04-20_009906Phase 3Completed
- Sponsor
- CymaBay Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in primary biliary cholangitis (PBC) comparing Seladelpar 10 mg with Placebo (2 arms). Primary endpoint: Primary endpoint not reported in registry entry. Started Apr 2021; status: completed.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on MOH_2021-04-20_009906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-20_009906.